Independent Verdict
COLOSSAL BIO OPPORTUNITIES, LLC is a newly formed Delaware investment vehicle with a verifiable SEC Form D filing dated September 18, 2026.
The issuer operates under CIK 0002155938 and disclosed a $15 million Rule 506(b) offering.
Public Form D tracking data reports approximately $2.2 million already sold to eight investors.
The filing is classified under Other Banking and Financial Services rather than biotechnology, which is important because the issuer appears to be an investment or special-purpose vehicle rather than Colossal Biosciences itself.
Public filing indexes associate COLOSSAL BIO OPPORTUNITIES, LLC with colossal.com.
Colossal.com is the official website of Colossal Biosciences, the genetics and bioscience company founded by Ben Lamm and George Church.
That creates a meaningful public connection between the investment vehicle and the Colossal ecosystem.
However, investors should not automatically assume that purchasing an interest in COLOSSAL BIO OPPORTUNITIES, LLC is legally identical to buying shares directly in Colossal Biosciences.
The central due-diligence question is therefore:
What security or economic interest does this LLC actually hold
That distinction matters more than the similarity of the names.
Key Findings
Issuer: COLOSSAL BIO OPPORTUNITIES, LLC
CIK: 0002155938
Entity Type: Limited Liability Company
Jurisdiction: Delaware
Formation Year: 2026
Filing Date: September 18, 2026
Filing Type: New Form D
Federal Exemption: Rule 506(b)
Industry Classification: Other Banking and Financial Services
Total Offering: $15,000,000
Reported Amount Sold: Approximately $2,200,000
Reported Investors: 8
Amount Remaining: Approximately $12,800,000
Associated Website: colossal.com
Public Brand Connection: Colossal Biosciences
Official Website: colossal.com
Colossal Founders: Ben Lamm and George Church
Colossal Business Focus: Genetics, bioscience, species restoration and de-extinction technologies
The $15 Million Offering Is Not a Colossal Biosciences Financing Round
This distinction is essential.
The SEC issuer is:
COLOSSAL BIO OPPORTUNITIES, LLC.
It is not:
Colossal Biosciences Inc.
The LLC has its own CIK and its own Form D.
The filing reports a $15 million offering with approximately $2.2 million sold to eight investors.
Therefore, FilingDossier would not describe this filing as:
"Colossal Biosciences raised $15 million."
That would merge two separate legal entities.
The safer interpretation is:
COLOSSAL BIO OPPORTUNITIES, LLC is raising up to $15 million through a private offering and public filing indexes connect the vehicle to the Colossal website.
Investors need the private placement documents to determine whether the LLC owns:
direct Colossal Biosciences shares,
preferred stock,
secondary shares,
a convertible instrument,
another investment vehicle,
or a broader portfolio of Colossal-related opportunities.
The Form D does not answer that question.
Why the $2.2 Million Sold Matters
The offering maximum is:
$15 million.
Approximately:
$2.2 million
had been reported sold.
That means roughly 14.7% of the stated offering had been subscribed at the time of the filing.
Eight investors were reported.
If the $2.2 million were divided equally, the average would be approximately:
$275,000 per investor.
That is only a mathematical reference point.
The filing does not state that all eight investors contributed equal amounts.
The more useful conclusion is that this appears to be an early-stage fundraising vehicle with a relatively small investor group at the initial filing date.
Colossal.com Can Be Independently Verified
The website connection is useful because colossal.com is not an empty or generic landing page.
It is the active official website of Colossal Biosciences.
The company describes itself as a genetics and bioscience business focused on species preservation, genetic engineering and de-extinction technologies.
Its official website identifies:
Ben Lamm
as Founder and CEO
and:
George Church, Ph.D.
as Founder.
The site also describes active scientific programs involving extinct and endangered species, genome engineering and reproductive technologies.
That creates a substantial operating company behind the Colossal brand.
But the existence of an operating company does not establish the precise economics of COLOSSAL BIO OPPORTUNITIES, LLC.
That legal link still needs to be verified from investment documents.
Why the Industry Classification Is Interesting
The Form D places the issuer in:
Other Banking and Financial Services.
That may initially look unusual for a vehicle using the Colossal name.
Colossal Biosciences itself is a biotechnology and genetics company.
One reasonable explanation is that COLOSSAL BIO OPPORTUNITIES, LLC functions as an investment vehicle rather than as the operating bioscience company.
This is consistent with the way SPVs and secondary-investment vehicles are often structured.
However, FilingDossier would not state that this is definitively a Colossal SPV until the underlying asset is confirmed.
The industry classification is a clue.
It is not proof of the investment structure.
The Colossal Brand Has Significant Public Visibility
Colossal Biosciences has a highly visible public profile.
Its official materials describe research involving:
Woolly mammoth restoration
Dire wolf research
Dodo-related science
Thylacine programs
Genetic rescue
Genome engineering
Embryology
and endangered-species preservation.
The company has also publicly announced partnerships and research initiatives involving universities and conservation organizations.
This gives investors substantial material for evaluating the operating company's scientific strategy.
But investors in COLOSSAL BIO OPPORTUNITIES, LLC need a separate layer of analysis.
They should ask:
Does the investment vehicle participate directly in Colossal Biosciences equity
At what valuation
What share class
What fees sit between the investor and the underlying company
Those questions determine the economics of the private investment.
What Investors Should Verify
Investors should obtain clear answers to the following:
What asset does COLOSSAL BIO OPPORTUNITIES, LLC own
Does it directly own shares of Colossal Biosciences
Is the investment primary or secondary
What class of Colossal shares is being acquired
What price per share is being paid
What valuation is being used
Does the LLC invest in only Colossal Biosciences
Can it invest in other companies
Who manages the LLC
What management fee applies
Is there a carried interest or performance fee
Are there organizational or administrative fees
How long is the expected holding period
Can investors redeem
What happens if Colossal remains private for many years
How are distributions handled after an IPO or acquisition
Can the manager distribute underlying shares rather than cash
Are there transfer restrictions
What information rights do investors receive
Does the LLC have voting rights in the underlying company
Are there any related-party transactions
What We Think
COLOSSAL BIO OPPORTUNITIES, LLC has an interesting public verification profile because the SEC filing and the Colossal website can both be identified, but the most important legal relationship remains partly hidden.
The SEC side is clear.
CIK 0002155938 exists.
The issuer was formed in Delaware in 2026.
The offering is $15 million.
Approximately $2.2 million had been reported sold to eight investors.
The exemption is Rule 506(b).
The website side is also clear.
Colossal.com is the official website of Colossal Biosciences, a real operating genetics and bioscience company led by Ben Lamm and co-founded with George Church.
What remains unclear from public Form D data is exactly what sits between those two facts.
That is the key diligence issue.
Investors should not treat the words "Colossal Bio Opportunities" as sufficient evidence that their LLC interest is economically identical to directly owning Colossal Biosciences stock.
The security documents need to establish that connection.
Risk Factors
Underlying Asset Transparency
The Form D does not publicly explain exactly what investment the LLC owns.
Single-Company Concentration
If the vehicle invests only in Colossal Biosciences, investor results may depend heavily on one private company.
Private Company Valuation Risk
Colossal Biosciences is privately held, meaning its shares do not have a continuously observable public market price.
Scientific Development Risk
Genetics and biotechnology programs can require substantial time, capital and scientific execution.
Liquidity Risk
Investors may be unable to sell their LLC interests before a liquidity event.
SPV Fee Risk
Management fees, carried interest or administrative expenses can reduce returns compared with direct ownership.
Structural Risk
Investors own an interest in COLOSSAL BIO OPPORTUNITIES, LLC, not automatically direct shares of Colossal Biosciences.
Exit Risk
A future IPO, acquisition or secondary transaction is not guaranteed.
Rule 506(b) Does Not Mean SEC Approval
The Form D filing confirms use of an exempt securities offering framework.
It does not mean the SEC approved the investment vehicle, Colossal Biosciences, its scientific programs, valuation or future returns.
Final Assessment
COLOSSAL BIO OPPORTUNITIES, LLC is a verifiable Delaware investment vehicle operating under SEC CIK 0002155938.
Its September 18, 2026 Form D reports a $15 million Rule 506(b) offering.
Public filing data reports approximately $2.2 million sold to eight investors.
Public Form D indexes also associate the issuer with colossal.com, the official website of Colossal Biosciences.
Colossal Biosciences itself is an identifiable genetics and bioscience company founded by Ben Lamm and George Church and focused on advanced genetic engineering, species restoration and de-extinction research.
That gives this investment vehicle a strong public-brand research trail.
However, the critical investment question remains unresolved by the Form D alone:
What exactly does COLOSSAL BIO OPPORTUNITIES, LLC own
Before investing, investors should verify whether the LLC holds direct Colossal Biosciences equity, the specific share class, acquisition price, valuation, management fees, carry, transfer restrictions, information rights and eventual distribution mechanics.
The strongest diligence approach is therefore to separate three things:
the SEC-registered Form D issuer,
the investment vehicle's legal economics,
and:
the underlying Colossal Biosciences operating company.
Those entities may be closely connected, but they should not be treated as legally identical without supporting documents.
SEC Form D is a notice filing for an exempt securities offering. It does not constitute SEC approval, verification of Colossal Biosciences' valuation, validation of its scientific programs or a guarantee of investor returns.
Published on FilingDossier: September 20, 2026.
This article is based on publicly available regulatory and company information and is provided for independent research and due-diligence purposes only.